Leaderboards/Colorectal and Anal Carcinomas

Colorectal and Anal Carcinomas

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Adele M. Nicolas
CeMM Research Center for Molecular Medicine
2
Fadl A. Zeineddine
Methodist Hospital
3
P.G.M. de Gooyer
The Netherlands Cancer Institute
4
Jindong Sheng
Tianjin Medical University Cancer Institute and Hospital
5
Alec Bigness
University of South Florida
6
Leilani Lakemeyer
University Hospital Ulm
7
Gangotri yadav
Swami Vivekanand College of Pharmacy
8
Keren Jia
Peking University
9
Joris L. Vos
Memorial Sloan Kettering Cancer Center
10
Stelios Theophanous
Leeds Teaching Hospitals NHS Trust

Papers

1
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Nature Medicine|2024
102 cit.
2
Publication in Pathology - Research and Practice (2024) [51 citations, W4390870506]
Pathology - Research and Practice|2024
51 cit.
3
Publication in The Innovation (2024) [47 citations, W4390667416]
The Innovation|2024
47 cit.
4
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
JCI Insight|2024
16 cit.
5
Publication in Signal Transduction and Targeted Therapy (2025) [13 citations, W4412019553]
Signal Transduction and Targeted Therapy|2025
13 cit.
6
247P Radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: The TARZAN study
Annals of Oncology|2024
8 cit.
7
503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
Annals of Oncology|2024
4 cit.
8
Publication in BMC Medicine (2026) [4 citations, W7122814482]
BMC Medicine|2026
4 cit.
9
Publication in Journal of Hepatology (2024) [W4399459527]
Journal of Hepatology|2024
0 cit.
10
Publication in Gynecologic Oncology (2024) [W4403251524]
Gynecologic Oncology|2024
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Lisa A. Gurski
National Comprehensive Cancer Network
2
Elizabeth Smyth
National Health Service
3
Thomas Winder
University of Southern California
4
Angela D. Motter
National Comprehensive Cancer Network
5
Naomi Jay
University of California, San Francisco
6
Lynn Hoang
Vancouver Coastal Health
7
Giby V. George
Natera (United States)
8
Seth Felder
Moffitt Cancer Center
9
Meiyun Wang
Henan Provincial People's Hospital
10
Alejandro Molina‐Leyva
Universidad de Granada

Papers

1
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology|2022
1.4k cit.
2
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
819 cit.
3
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology|2022
656 cit.
4
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
655 cit.
5
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Journal of the National Comprehensive Cancer Network|2022
302 cit.
6
International Anal Neoplasia Society's consensus guidelines for anal cancer screening
International Journal of Cancer|2024
271 cit.
7
Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
236 cit.
8
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
215 cit.
9
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network|2024
166 cit.
10
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
ESMO Open|2024
90 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Dirk Arnold
Asklepios Klinik Altona
2
Richard J. Heald
Basingstoke and North Hampshire Hospital
3
Kenichi Sugihara
Toujinkai Hospital
4
Christopher G. Willett
Unknown
5
Madappa N. Kundranda
The University of Texas MD Anderson Cancer Center
6
Toshiaki Watanabe
National Center For Child Health and Development
7
Gregor B. E. Jemec
Gentofte Hospital
8
Steven Gallinger
Ontario Institute for Cancer Research
9
Thierry André
Inserm
10
Gina Brown
Imperial College Healthcare NHS Trust

Papers

1
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Case Reports in Oncology|2015
5.3k cit.
2
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
New England Journal of Medicine|2004
3.7k cit.
3
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology|2016
3.4k cit.
4
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
New England Journal of Medicine|2020
3k cit.
5
The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?
British journal of surgery|1982
2.9k cit.
6
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology|2017
2.8k cit.
7
RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCER
The Lancet|1986
2.7k cit.
8
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
International Journal of Clinical Oncology|2017
2.5k cit.
9
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Journal of Clinical Oncology|2009
2.3k cit.
10
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
New England Journal of Medicine|2003
2.1k cit.

Reagents for Colorectal and Anal Carcinomas

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

SirT1 Antibody

#2028$317
View Evidence →
Leica BiosystemsEvidence 77

CD8, Liquid Concentrate

#CD8-4B11-L-U (also NCL-L-CD8-4B11-U)
View Evidence →
Cell Signaling TechnologyEvidence 64

Phospho-Met (Tyr1003) Matched Antibody Pair

#72698$1,726
View Evidence →

🌟 All-Time

Most validated

Leica BiosystemsEvidence 78

Anti-CD4 and CD8 duo pack Monoclonal Antibody, Unconjugated

#NCL-CD4/CD8d
View Evidence →
RocheEvidence 75

VENTANA® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody

#760-5095 (also 08033706001)
View Evidence →
Leica BiosystemsEvidence 77

CD 4, T-cell surface glycoprotein

#NCL-CD4-1P
View Evidence →